Abstract 1573P
Background
Concurrent chemoradiation is standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), while the optimal regimen of radiotherapy, especially in terms of total dose and planned range of target field, remained unclear. We performed this phase III clinical trial (ChiCTR-IPR-15007172) to compare the survival benefits between different radiation dose and different target field.
Methods
This trial compared two radiation treatment aspects of total dose and field under two-by-two factorial design. The involved field irradiation (IFI) group and elective nodal irradiation (ENI) group adopted different radiation plans of clinical target volume. The high radiation dose group (HD) totally received 59.4Gy radiation and standard dose group (SD) received 50.4 Gy. The participants were assigned to one of the four groups (HD+ENI, HD+IFI, SD+ENI and SD+IFI) by simple randomization (1:1:1:1 ratio). The planned sample size was 147 in each arm (588 totally) and the primary endpoint was overall survival (OS). All statistical analysis was performed according to intention-to-treat principle.
Results
The median follow-up time reached 64.6 months up to April 2023. In comparison of target field, patients in IFI or ENI presented similar OS (HR=0.99, log rank test p =0.93) and PFS (HR=1.02). The HD treatment did not present significantly prolonged OS (HR=0.90, log rank test p value=0.318) compared with SD but suggested improved PFS (25.2 months to 18.0 months, HR=0.76). No significant synergistic effect was detected between dose and radiation field in interaction analysis (p=0.11). In subgroup analysis, the HD radiation suggested benefits in T4 tumors, and the ENI treatment was associated with better OS in N0 patients. No significant difference in occurrences of severe adverse events was detected in dose or field comparisons.
Conclusions
The IFI has similar treatment efficiency to ENI, which indicated a reasonable choice for locally advanced ESCC. HD radiation did not suggest significant benefits in OS, but associated with better PFS compared to SD.
Clinical trial identification
ChiCTR-IPR-15007172.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the grants of Key Research and Development Program of Shandong Province of China, 2017CXZC1206, National Natural Science Foundation of China, 81874224, Academic promotion program of Shandong First Medical University, China, 2019LJ004, Key Research and Development Program of Shandong Province, 2021LCZX04 and Key Research and Development Program of Shandong Province, 2021SFGC0501.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22